Bank NPAs may jump to 4.4% under severe stress: RBI
Gross NPA ratio of all scheduled commercial banks declined to an 11-year low of 3.2% at the end of September 2023.
non performing assets
December 2023
July 2023
June 2023
March 2023
November 2022
May 2021
April 2021
Banks' GNPAs at decadal low of 3.2% as of Sep 2023: RBI
45% cut in gross NPAs contributed by "recoveries and upgradations", shows RBI data
NPAs: RBI must name and shame fraudsters, wilful defaulters
RBI must make public the debtors who are marked 'fraud' and 'wilful defaulter' to stop money laundering, fleeing the country and also to prevent negligence of banks, law enforcement agencies, if any
NPAs Under Tight Leash
Non-performing assets have dipped but it's too early to uncork the bubbly as global slowdown impacts export and MSME sectors.
BoM: Changing The Credit Culture
From scanning portfolios to identifying deficiencies in loan sanctions, to central processing cells, Bank of Maharashtra has come a long way.
Banks' NPAs drop to 10-year low in March
Profit of Indian lenders grew 38.4% in 2022-23, led by strong growth in net interest income and significant reduction in provisions
PNB sells entire stake in ARCIL to Avenue India Resurgence
The PSU lender has sold its entire 10.01% stake in the asset reconstruction company in a cash transaction.
Yes Bank to transfer stressed assets worth ₹48,000 cr to JC Flowers by November-end
In July, the private lender selected JC Flowers for the sale of its stressed loans after a consortium of Cerberus Capital and Asset Reconstruction Company of India (ARCIL) withdrew from the bid.
RBI announces steps to fight second wave of Covid-19
The central bank unveils liquidity facility of ₹50,000 crore for access to emergency health services, and ₹10,000 crore for small finance banks’ on-lending, among a slew of measures to fight Covid-19.
Cautiously optimistic credit outlook for FY22: CRISIL
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
